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ABSTRACT 
The objective of the present work was to develop drug loaded niosomal ophthalmic formulation of timolol maleate (an 
antiglaucomal drug) for enhanced trans-corneal drug permeation and better ocular bioavailability. Timolol loaded niosomes were 
prepared by thin film hydration method using rotary evapoarator and ultra-sonicated for size reducation using probe sonicator. The 
nano-vesicle (niosomal) formulation was optimized by selecting surfactant content, cholesterol content and sonication time as 
independent variables and particle (vesicle) size, drug entrapment efficiency and % drug release as response variables for 
optimization studies. The timolol maleate niosomal (TMN) formulation was evaluated for particle size, pH and osmolality and was 
found to possess the desired properties. The developed TMN formulation was studied for % cumulative in-vitro drug release using 
bottle rotating apparatus (electrolab) and was found to be 79.98% over 8 hr period exhibiting sustained drug release profile. The ex-
vivo trans-corneal drug permeation profile of developed TMN was studied using modified franz-diffusion cell apparatus (Permegear) 
and the % cumulative drug permeation across freshly excised goat cornea was found to be 65.90 % in 8 hrs duration, which was 
approximately 1.5 times higher than the conventional eye drop formulation. The developed TMN was also proved to be isotonic and 
non-irritant in HET-CAM ocular irritancy test. It was therefore, concluded from above studies, that the developed timolol maleate 
niosomal (TMN) formulation is better than conventional eye drops due to longer corneal retention, sustained drug release and better 
trans-corneal drug permeation and thereby higher ocular bioavailability, hence, would need less frequent administration.  
 
Cite this article as: Soni PK, Saini TR, Non-Ionic surfactant vesicles (Niosomes) based novel ophthalmic formulation of timolol 
maleate , Journal of Drug Delivery and Therapeutics. 2017; 7(7):59-61 
 
INTRODUCTION: 
Timolol maleate, a non-selective beta blocker, is widely 
used for treatment of glaucoma in the form of eye drops, 
however, the conventional eye drop formulations suffer 
from inadequate ocular bioavailability and need to be 
frequently administered, due to their short pre-corneal 
residence, naso-lacrymal drainage and poor trans-
corneal permeation. It was, therefore, aimed to develop 
nano-vesicular (niosomal) ophthalmic formulation of 
timolol maleate for enhanced trans-corneal permeation 
and ocular bioavailability. Niosome based novel 
formulations are being extensively explored due to their 
inherent advantages in drug delivery system 
1
.
 
MATERIAL AND METHODS: 
Material 
Timolol maleate was received as gift sample from M/s. 
Piramal Healthcare Ltd. Pihampur (MP). Span-60 (Loba 
Chemie) and Cholesterol (Merck) was purchased from 
local market. All other chemicals, reagents and solvents 
used were of analytical grade. 
Formulation of Timolol maleate niosome (TMN) 
Timolol maleate loaded niosomes were prepared by thin-
film hydration method 2 using rotary evaporator 
(Buchi
®
).  
Determination of particle size and entrapment 
efficiency  
The niosomal dispersion obtained as above was 
sonicated for 2-3 minutes using ultra-probe sonicator 
(sonics) for converting the niosomes to nanometric size 
range and the particle (vesicle) size distribution of TMN 
formulation was determined by Nanotrac nano-particle 
size analyzer (Microtrac Inc.). The timolol maleate 
loaded niosomes were separated from free drug 
(unentrapped drug) by centrifugation at 13,000 rpm and 
4°C using refrigerated centrifuge (Eppendorf). The clear 
supernatant so obtained was analyzed for estimation of 
drug content and the amount of unentrapped drug was 
calculated. Amount of entrapped drug was obtained by 
subtracting amount of unentrapped drug from the total 
drug amount taken 
3
. 
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In vitro drug release study 
In vitro drug release study of the developed TMN 
formulation was performed in Bottle rotating apparatus. 
In this method, an accurately weighed quantity of 
timolol maleate niosomes (equivalent to 2 mg drug), was 
suspended in 10 ml phosphate buffer (pH 7.4) filled in 
the capped  glass bottle (tube) and rotated at 25 rpm and 
maintained at 37
0
C. One test sample bottle (tube) was 
taken out every one hour and was analyzed for 
estimation of drug release till 8 hour duration and 
thereby, the % cumulative drug release was calculated 
for a period of 8 hr. 
Ex vivo Trans-corneal Drug Permeation Study 
Trans-corneal drug permeation study of developed TMN 
formulation was carried out under ex-vivo condition 
across freshly excised goat cornea using modified franz-
diffusion cell apparatus and was compared to that of 
conventional eye drop product. The exposed area of 
goat’s cornea was 1.130 cm2 4.        
Isotonicity evaluation 
Red blood cells were separated from freshly collected 
blood from slaughter by centrifugation applying 
centrifugal force of 14000G for 10 min using cooling 
centrifuge (Eppendorf). The recovered RBCs were 
suspended in appropriate amount of developed TMN 
formulation, 0.9% saline (isotonic) solution (negative 
control), and hypotonic & hypertonic saline solution 
(positive control) was  vortexed for 5 min and was kept 
aside for 30 min and subsequently observed under the 
polarizing microscope (Leica) at 40X magnification.  
HET-CAM Ocular irritancy test 
The purpose of this test to evaluate the potential ocular 
irritancy of a test substance as measured by its ability to 
induce toxicity in the chorio-allantoic membrane (CAM) 
of a chicken embryo in fertilized hens egg. In this test, 
irritancy is assessed by the onset of hemorrhage, 
coagulation and vessel lysis. These assessments are 
considered individually and then combined to derive a 
score; irritation score (IS) which is used to classify the 
irritancy level of the test substance.  
RESULTS AND DISCUSSION: 
The various physico-chemical properties i.e., particle 
size, polydispersity index, pH, osmolality and % 
entrapment efficiency was studies and the results 
observed are presented in Table 1 
Table 1: Physico-chemical properties of developed 
TMN formulation 
S. N. Properties Result 
1 Particle size 226.29 nm 
2 Osmolality 298 mOsm/kg 
3 % Entrapment efficiency 42.88% 
 
The developed TMN formulation was studied for % 
cumulative in-vitro drug release using bottle rotating 
apparatus (electrolab) and was found to be 79.98% over 
8 hr period exhibiting sustained drug release profile. The 
ex-vivo trans-corneal drug permeation profile of 
developed TMN was studied using modified franz-
diffusion cell apparatus (Permegear) and the % 
cumulative drug permeation across freshly excised goat 
cornea was found to be 65.90 % in 8 hrs duration, which 
was approximately 1.5 times higher than the 
conventional eye drop formulation, as shown in figure 1. 
 
Figure 1: Trans-corneal Drug Permeation Profile of 
Timolol Maleate Niosomal Formulation 
The developed TMN was also proved to be isotonic in 
isotonicity studies, as the isolated RBCs were normal in 
size and shape on exposure with developed TMN and 
isotonic saline solution, while the RBCs were shrink in 
hypotonic and swollen in hypotonic solution and are 
shown in figure 2.  
                 
       
(a)                                (b)                                  (c)                                    (d) 
Figure 2: (a) RBCs with Developed Timolol Maleate Niosomal Eye Drop, (b) RBCs with Isotonic Solution (c) RBCs 
with Hypotonic Solution (d) RBCs with Hypertonic Solution 
The developed timolol maleate niosomal formulation 
was also proven to be non-irritant in HET-CAM ocular  
irritancy test securing 0 score, as there were no signs of 
hemorrahage, lysis and coagulation in CAM of fertilized 
hens egg with developed TMN and isotonic saline 
solution (negative control), while hemorrahage was 
observed with 1% NaOH solution (positive control), as 
shown in fig.3. 
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Figure 3: HET-CAM response to exposure with TMN formulation, negative control and positive control 
 
CONCLUSION: 
It can be concluded from above studies, that the 
developed timolol maleate niosomal (TMN) formulation 
is better than conventional eye drops due to longer 
corneal retention, sustained drug release and better 
trans-corneal drug permeation and thereby higher ocular 
bioavailability, hence, would need less frequent 
administration.
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